Upon joining the study, you will be randomly assigned to receive either the study medication, omecamtiv mecarbil, or a placebo. A placebo is a tablet that looks like the study medication but does not contain the active ingredient.

The study is designed to be double-blind, meaning neither you nor the study team will know which treatment you are receiving. This helps ensure the results are unbiased.

You will take the assigned medication orally in the form of a film-coated tablet. The exact dosage and frequency will be provided by the study team based on your specific needs and the study protocol.

It is important to take the medication as directed and report any side effects or concerns to the study team immediately.

Throughout the study, you will have regular check-ups with the study team. These visits are crucial for monitoring your health and the effects of the medication.

During these visits, various tests and assessments will be conducted to evaluate your heart function and overall health.

You will be asked to keep track of any symptoms or changes in your health. This information is vital for understanding how the medication affects you.

The study team will provide you with a diary or other tools to help you record this information accurately.

At the end of your participation in the study, you will have a final visit with the study team. This visit will include a comprehensive assessment of your health and a discussion of your experience during the study.

The study team will also provide information on any next steps or follow-up care that may be necessary.